- Home
- BRNS vs DYAI Comparison
BRNS vs DYAI Comparison
Compare BRNS & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- DYAI
- Stock Information
- Founded
- BRNS 2016
- DYAI 1979
- Country
- BRNS United Kingdom
- DYAI United States
- Employees
- BRNS N/A
- DYAI N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRNS Health Care
- DYAI Health Care
- Exchange
- BRNS Nasdaq
- DYAI Nasdaq
- Market Cap
- BRNS 38.7M
- DYAI 31.3M
- IPO Year
- BRNS 2021
- DYAI 2004
- Fundamental
- Price
- BRNS $1.08
- DYAI $1.04
- Analyst Decision
- BRNS Strong Buy
- DYAI Strong Buy
- Analyst Count
- BRNS 2
- DYAI 1
- Target Price
- BRNS $3.00
- DYAI $6.00
- AVG Volume (30 Days)
- BRNS 53.8K
- DYAI 46.4K
- Earning Date
- BRNS 05-07-2025
- DYAI 05-14-2025
- Dividend Yield
- BRNS N/A
- DYAI N/A
- EPS Growth
- BRNS N/A
- DYAI N/A
- EPS
- BRNS N/A
- DYAI N/A
- Revenue
- BRNS $14,969,000.00
- DYAI $3,554,344.00
- Revenue This Year
- BRNS N/A
- DYAI $78.01
- Revenue Next Year
- BRNS N/A
- DYAI N/A
- P/E Ratio
- BRNS N/A
- DYAI N/A
- Revenue Growth
- BRNS 4381.74
- DYAI 57.59
- 52 Week Low
- BRNS $0.64
- DYAI $0.93
- 52 Week High
- BRNS $2.14
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- BRNS 60.08
- DYAI 42.88
- Support Level
- BRNS $0.65
- DYAI $0.93
- Resistance Level
- BRNS $1.11
- DYAI $1.13
- Average True Range (ATR)
- BRNS 0.13
- DYAI 0.08
- MACD
- BRNS 0.02
- DYAI 0.01
- Stochastic Oscillator
- BRNS 93.42
- DYAI 53.50
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.